An open label SLV308 [pardoprunox] safety extension to study S308.3.001 in early PD [Parkinson's disease] patients.

Trial Profile

An open label SLV308 [pardoprunox] safety extension to study S308.3.001 in early PD [Parkinson's disease] patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Pardoprunox (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Primary outcome amended as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Planned patient numbers amended from 300 to 224 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top